Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia

NEW YORK, Dec. 11, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news

Related Links:

In Reply We are gratified to know that the FDA is developing guidance that supports inclusion of individuals with suicidal ideation or behavior associated with serious mental illnesses, including schizophrenia and bipolar disorder, in clinical trials. W...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news
Publication date: Available online 18 March 2019Source: International Journal of PsychophysiologyAuthor(s): Annarita Vignapiano, Thomas Koenig, Armida Mucci, Giulia M. Giordano, Antonella Amodio, Mario Altamura, Antonello Bellomo, Roberto Brugnoli, Giulio Corrivetti, Giorgio Di Lorenzo, Paolo Girardi, Palmiero Monteleone, Cinzia Niolu, Silvana Galderisi, Mario Maj, The Italian Network for Research on PsychosesAbstractIn subjects with schizophrenia (SCZ), the disorganization dimension is a strong predictor of real-life functioning. “Conceptual disorganization” (P2), “Difficulty in abstract thinking” ...
Source: International Journal of Psychophysiology - Category: Psychiatry & Psychology Source Type: research
Publication date: Available online 16 March 2019Source: Progress in Neuro-Psychopharmacology and Biological PsychiatryAuthor(s): Katharina M. Kubera, Mahmoud Rashidi, Mike M. Schmitgen, Anja Barth, Dusan Hirjak, Fabio Sambataro, Vince D. Calhoun, Robert C. WolfAbstractThere is accumulating neuroimaging evidence for both structural and functional abnormalities in schizophrenia patients with persistent auditory verbal hallucinations (AVH). So far, the direct interrelationships between altered structural and functional changes underlying AVH are unknown. Recently, it has become possible to reveal hidden patterns of neural dys...
Source: Progress in Neuro Psychopharmacology and Biological Psychiatry - Category: Psychiatry Source Type: research
Publication date: Available online 22 November 2017Source: NeuroImageAuthor(s): Emmi Mikanmaa, Tineke Grent-'t-Jong, Lingling Hua, Marc Recasens, Hanna Thune, Peter J. UhlhaasAbstractThe identification of biomarkers for the early diagnosis of schizophrenia that could inform novel treatment developments is an important objective of current research. This paper will summarize recent work that has investigated changes in oscillatory activity and event-related potentials with Electro/Magnetoencephalography (EEG/MEG) in participants at high-risk for the development of schizophrenia, highlighting disruptions in sensory and cogni...
Source: NeuroImage - Category: Neuroscience Source Type: research
In this study, there was no significant relationship between disease genotype for DISC1 gene and schizophrenia. By increasing the heterozygote genotype in the population, the probability of the disease will increase and mutant homozygote genotypes will also be visible.
Source: Meta Gene - Category: Genetics & Stem Cells Source Type: research
ConclusionsAsymmetric WM alterations were found in a frontal tract of patients with schizophrenia. Higher mean FA in the right frontal tract correlated with worse verbal memory performance, suggesting a possible contribution these brain changes to cognitive impairment in schizophrenia.
Source: NeuroImage: Clinical - Category: Radiology Source Type: research
I plead guilty to expounding on the biochemical vulnerabilities and abnormalities in neural wiring of depression to make the case that it is a legitimate illness alongside lupus, breast cancer, or psoriatic arthritis. I thought I was doing a good thing by quoting experts like Peter Kramer, M.D, who believes that because depression can be associated with the loss of volume in parts of the brain, it is the “most devastating disease known to mankind.” My intention, like so many other mental health advocates I know, was to use science as a tool to lessen stigma. But is that really effective? Proof of the Madness I ...
Source: World of Psychology - Category: Psychiatry & Psychology Authors: Tags: Brain and Behavior Depression General Mental Health and Wellness Psychiatry Psychology Research Self-Help Treatment biogenetic theory Depressive Episode Mental Illness Mood Disorder Stereotypes Stigma Source Type: blogs
In Reply We are gratified to know that the FDA is developing guidance that supports inclusion of individuals with suicidal ideation or behavior associated with serious mental illnesses, including schizophrenia and bipolar disorder, in clinical trials. We agree that trial participants with acute suicidal ideation or behavior, including those in the control groups of clinical trials evaluating suicidal ideation or behavior as an end point, be provided with standard-of-care (including emergency) interventions or with investigational approaches hypothesized to be as good as or better than the standard of care. However, mandati...
Source: JAMA - Category: General Medicine Source Type: research
This article will briefly review the clinical signs, symptoms and proposed etiologies of schizophrenia, and describe the current understanding of exercise programs as an effective treatment in patients with the disease. PMID: 30858639 [PubMed - in process]
Source: Psychopharmacology Bulletin - Category: Psychiatry & Psychology Tags: Psychopharmacol Bull Source Type: research
.
Source: Journal of Mental Health - Category: Psychiatry Authors: Source Type: research
More News: Drugs & Pharmacology | New Drug Applications | Schizophrenia